Literature DB >> 18766374

Reduced rate of adverse reactions to the BCG vaccine in children exposed to the vertical transmission of HIV infection and in HIV-infected children from an endemic setting in Brazil.

Regina Célia de Souza Campos Fernandes1, Luciana Cordeiro de Araújo, Enrique Medina-Acosta.   

Abstract

We report on the adverse reactions to the Bacillus Calmette-Guérin (BCG) vaccine in BCG-vaccinated children. We examined children exposed to the vertical transmission of human immunodeficiency virus (HIV) (n = 141), who participated in a prevention program of vertical transmission, and HIV-infected children (n = 66) in a setting endemic for HIV and tuberculosis (TB) in Brazil from August 2000 to February 2008. No cases of disseminated BCG disease occurred in either group of children. While no cases of regional BCG disease were noted in exposed/uninfected children, the rate of regional BCG disease in HIV-infected children was 4.5% (3/66); the three events occurred in <1-year-old children (3/17; 17.6%). One case was associated with severe immunodepression before highly active antiretroviral therapy (HAART). Two cases were manifestations of immune reconstitution inflammatory syndrome (IRIS). Among the HIV-infected children, the accrued benefits of potentially preventing severe TB outweighed the risks associated with the use of the BCG vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18766374     DOI: 10.1007/s00431-008-0822-y

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  32 in total

1.  National study of adverse reactions after vaccination with bacille Calmette-Guérin.

Authors:  F M Turnbull; P B McIntyre; H M Achat; H Wang; R Stapledon; M Gold; M A Burgess
Journal:  Clin Infect Dis       Date:  2002-01-04       Impact factor: 9.079

2.  Brazilian report on primary immunodeficiencies in children: 166 cases studied over a follow-up time of 15 years.

Authors:  A S Grumach; A J Duarte; R Bellinati-Pires; A C Pastorino; C M Jacob; C L Diogo; A Condino-Neto; M Kirschfink; M M Carneiro-Sampaio
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

3.  Regional Bacillus Calmette-Guérin lymphadenitis after initiating antiretroviral therapy in an infant with human immunodeficiency virus type 1 infection.

Authors:  M J Sharp; D F Mallon
Journal:  Pediatr Infect Dis J       Date:  1998-07       Impact factor: 2.129

Review 4.  Disseminated bacille Calmette-Guérin disease after vaccination: case report and review.

Authors:  E A Talbot; M D Perkins; S F Silva; R Frothingham
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

5.  Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children.

Authors:  A C Hesseling; H Rabie; B J Marais; M Manders; M Lips; H S Schaaf; R P Gie; M F Cotton; P D van Helden; R M Warren; N Beyers
Journal:  Clin Infect Dis       Date:  2006-01-11       Impact factor: 9.079

6.  The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children.

Authors:  Anneke C Hesseling; Ben J Marais; Robert P Gie; H Simon Schaaf; Paul E M Fine; Peter Godfrey-Faussett; Nulda Beyers
Journal:  Vaccine       Date:  2006-08-01       Impact factor: 3.641

7.  Detection of bloodstream pathogens in a bacille Calmette-Guérin (BCG)-vaccinated pediatric population in Malawi: a pilot study.

Authors:  L K Archibald; O Nwanyanwu; P N Kazembe; C Mwansambo; M Bell; H Dobbie; L B Reller; W R Jarvis
Journal:  Clin Microbiol Infect       Date:  2003-03       Impact factor: 8.067

8.  Chapter 5: Health staff roles and responsibilities, recording and reporting and BCG vaccination.

Authors: 
Journal:  Int J Tuberc Lung Dis       Date:  2007-02       Impact factor: 2.373

9.  [Prevention of vertical HIV transmission in Campos dos Goytacazes, Rio de Janeiro, Brazil].

Authors:  Regina Célia de Souza Campos Fernandes; Luciana Cordeiro de Araújo; Enrique Medina-Acosta
Journal:  Cad Saude Publica       Date:  2005-07-11       Impact factor: 1.632

10.  Mycobacterium bovis dissemination (BCG strain) among immunodeficient Brazilian infants.

Authors:  C M Jacob; A C Pastorino; A M Azevedo; H H Marques; H K Sato; L Ferrazole; M Z Aquino; P T Sakane; A S Grumach
Journal:  J Investig Allergol Clin Immunol       Date:  1996 May-Jun       Impact factor: 4.333

View more
  3 in total

1.  Undervaccination of perinatally HIV-infected and HIV-exposed uninfected children in Latin America and the Caribbean.

Authors:  Regina C M Succi; Margot R Krauss; D Robert Harris; Daisy M Machado; Maria Isabel de Moraes-Pinto; Marisa M Mussi-Pinhata; Noris Pavia Ruz; Russell B Pierre; Lenka Kolevic; Esau Joao; Irene Foradori; Rohan Hazra; George K Siberry
Journal:  Pediatr Infect Dis J       Date:  2013-08       Impact factor: 2.129

2.  Incidence of opportunistic illness before and after initiation of highly active antiretroviral therapy in children.

Authors:  Steven R Nesheim; Felicia Hardnett; John T Wheeling; George K Siberry; Mary E Paul; Patricia Emmanuel; Beverly Bohannon; Kenneth Dominguez
Journal:  Pediatr Infect Dis J       Date:  2013-10       Impact factor: 2.129

3.  Tuberculosis in HIV-infected infants, children, and adolescents in Latin America.

Authors:  Margot R Krauss; D Robert Harris; Thalita Abreu; Fabiana G Ferreira; Noris Pavia Ruz; Carol Worrell; Rohan Hazra
Journal:  Braz J Infect Dis       Date:  2014-10-11       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.